Sign up to save your podcasts
Or
Share Use of Marstacimab for Prophylaxis in hemophilia A and B; matched-donor allogeneic CD19 CAR-T in adult B-ALL; a new prognostic index for T-cell cutaneous lymphomas
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Use of Marstacimab for Prophylaxis in hemophilia A and B; matched-donor allogeneic CD19 CAR-T in adult B-ALL; a new prognostic index for T-cell cutaneous lymphomas
In this week's episode we'll learn about targeting the tissue factor pathway inhibitor with a monoclonal antibody to rebalance HEMOSTASIS in hemophilia A and B. In the phase 3 BASIS trial, the monoclonal antibody marstacimab reduced bleeding events, and was generally well tolerated, with no unanticipated side effects. After that: matched-donor allogeneic CD19 CAR-T for adult B-ALL. Given after allogeneic transplantation, CAR-donor lymphocyte infusion after lymphodepleting chemotherapy was associated with favorable efficacy and a tolerable safety profile. Finally: a new prognostic index for mycosis fungoides and Sézary syndrome. Comprised of four prognostic factors, the “CLIPI” could enable more personalized treatment of cutaneous lymphomas, identifying patients who may benefit from intensified treatment.
Featured Articles
- Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial
- Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion
- A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification
View all episodes
By American Society of Hematology
4.1
4949 ratings
In this week's episode we'll learn about targeting the tissue factor pathway inhibitor with a monoclonal antibody to rebalance HEMOSTASIS in hemophilia A and B. In the phase 3 BASIS trial, the monoclonal antibody marstacimab reduced bleeding events, and was generally well tolerated, with no unanticipated side effects. After that: matched-donor allogeneic CD19 CAR-T for adult B-ALL. Given after allogeneic transplantation, CAR-donor lymphocyte infusion after lymphodepleting chemotherapy was associated with favorable efficacy and a tolerable safety profile. Finally: a new prognostic index for mycosis fungoides and Sézary syndrome. Comprised of four prognostic factors, the “CLIPI” could enable more personalized treatment of cutaneous lymphomas, identifying patients who may benefit from intensified treatment.
Featured Articles
- Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial
- Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion
- A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification
More shows like Blood Podcast
View all
TED Talks Daily
11,140 Listeners
JAMA Editors' Summary
141 Listeners
NEJM This Week
319 Listeners
JAMA Clinical Reviews
500 Listeners
Hematologic Oncology Update
75 Listeners
The Hematologist
26 Listeners
Core IM | Internal Medicine Podcast
1,156 Listeners
VJHemOnc Podcast
2 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
363 Listeners
The Curious Clinicians
373 Listeners
EHA Unplugged
1 Listeners
Blood Cancer Talks
48 Listeners
Two Onc Docs
190 Listeners
WolverHeme Happy Hour
30 Listeners
HemeTalks: Conversations in Hematology Education
4 Listeners